Thank you for Subscribing to CIO Applications Weekly Brief

Unlock Tumor Microenvironment Insights Powered by AI
PathExplore will enable researchers to identify novel spatial signatures predictive of outcomes.
By
CIO Applications | Monday, August 07, 2023

The PathExplore panel from PathAI offers oncology drug developers spatial characterization of tumor microenvironments, propelling precision medicine to a new level.
FREMONT, CA: "PathExplore will enable researchers to identify novel spatial signatures predictive of outcomes," said Andy Beck, M.D., Ph.D., chief executive officer and co-founder of PathAI. "We're hopeful that by giving oncology drug developer’s access to this level of detail and data from routine H&E samples, this next generation of pathology will drive advances in cancer therapy development."
PathExplore, the first organized, standardized, and scalable panel of human interpretable features (HIFs) giving an unparalleled resolution of the tumor microenvironment (TME) from H&E whole-slide pictures, has been released by PathAI, a leader in AI-powered pathology. Using single-cell resolution and artificial intelligence, PathExplore1 spatially describes the TME, enabling cancer drug developers to gain knowledge to guide the next stage of targeted oncology medication development.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Oncology therapeutic development has made great achievements over the past ten years, but there are still obstacles to overcome. For example, many cancer patients don't respond to current treatments, and many more aren't eligible for potentially game-changing treatments because there isn't enough actionable knowledge about their condition. One of the most promising areas of cancer research, the tumor microenvironment, is being studied by researchers to gain knowledge and understanding that would improve patient outcomes.
Researchers are forced to choose between resolution and scalability when measuring and analyzing the TME. Drug makers can now study the TME in great detail utilizing a scalable platform that can be used on many patient samples thanks to PathExplore. A panel of more than 600 quantitative HIFs—standardized, repeatable measurements of counts, densities, areas, and spatial correlations among various cell types and tissue regions—are created by PathExplore. On PathAI's AISightTM Translational Research platform, PathExplore also creates overlay representations of various cell types and tissue locations.
Over 6.5 million pathologist annotations on 66,000 slides were used to train PathExplore. It is already approved for treating breast cancer, colorectal cancer, gastric cancer, melanoma, non-small cell lung cancer, pancreatic cancer, prostate cancer, and renal cell carcinoma, with the approval of ovarian and bladder malignancies expected later this year. Reproducible, comparable, and scaleable analysis across medication programs will be made possible by the uniform, systematic measurement of the TME across disease areas.
"PathExplore will shift the research paradigm, bypassing long-standing constraints we experience with some of the existing multi-omics modalities and allowing for more open exploration and discovery of relationships that were not identifiable by human analysis alone," said Mike Montalto, Ph.D., chief scientific officer at PathAI. "The degree of granularity, speed, efficiency, and scale delivers unmatched insights that will change the way we view the tumor microenvironment."
More in News

